Reprocell and Fox Chase to open biosample repository in India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Reprocell USA, a subsidiary of Japan’s Reprocell Inc., and Fox Chase Ltd., one of the Fox Chase Cancer Center organizations, formed a joint venture to operate a multi-site bio-sample repository facility in India.

Initial operations are underway in Delhi with plans to expand to Hyderabad later this year. The facilities will add approximately 3,000 new bio-samples monthly. Collected specimens will be supported by annotations that include medical history, mutation data and detailed records of treatment protocols as well as outcomes.

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login